Additionally, semaglutide slows gastric emptying, meaning food stays in the stomach longerprolonging the feeling of fullness after meals. These combined effects explain why semaglutide for weight loss has become a widely discussed and clinically validated approach in obesity management
With the exception of STEP 5 [40] and STEP 10 [42], which differed in trial duration, and STEP 8 [46], which included an active comparator (liraglutide), all trials followed a standardised 68-week treatment period
Clinical data from Epiphany treatments indicates significant results, with patients achieving up to 15% body weight reduction within three months and a 24% decrease in cardiovascular event risks
Despite these high prescription numbers, the actual number of users may be even greater, as some obtain the medication without adequate medical supervision, often due to insurance limitations